サマリー

The United States platelet rich plasma market grew at a CAGR of around 10% during 2015-2020. Looking forward, IMARC Group expects the market to continue its strong growth during 2021-2026. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.

Platelet-rich plasma (PRP) refers to a concentrated plasma protein that contains minor quantities of red blood cells. The platelets are suspended in a small amount of plasma after centrifugation and stimulate healing when injected into the body. PRP is widely administered by non-invasive therapies for long-lasting rejuvenation of ligaments and muscle fibers. Some of the common variants of PRP include pure platelet-rich plasma (P-PRP), leukocyte- and platelet-rich plasma (LPRP), leukocyte- and platelet-rich Fibrin (L-PRF), and pure platelet-rich fibrin (P-PRF).

The rising prevalence of chronic tendon injuries in vital organs is currently bolstering the demand for PRP-based therapies in the US. Furthermore, increasing adoption of effective therapies for treating muscle and acute ligament tearing, arthritis, fractures, orthopedic impairments, etc., is also propelling the market growth. In line with this, the growing awareness towards numerous benefits of PRP treatment in preventing inflammation, encouraging new cartilage formulation, and inducing natural lubrication fluid production, is further augmenting the product demand in the country. Moreover, the rising deployment of advanced healthcare facilities for sports clubs and teams is also catalyzing the adoption of PRP-based therapies for treating common injuries in athletes, such as lumbar spine disc pain, rotator cuff injuries, shoulder pain and instability, tennis/golfer’s elbow, etc. Apart from this, the expanding cosmetic surgery sector in the United States is further driving the utilization of PRP-based procedures for improving facial shape and volume. In the coming years, the increasing healthcare expenditures along with the rising demand for non-invasive medical procedures will continue to spur the demand for PRP-based therapies in the United States.

Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the United States platelet rich plasma market, along with forecasts at the country and regional level from 2021-2026. Our report has categorized the market based on product type, origin, application and end user.

Breakup by Product Type:

Pure Platelet-Rich Plasma (P-PRP)
Leukocyte- and Platelet-Rich Plasma (LPRP)
Leukocyte- and Platelet-Rich Fibrin (L-PRF)
Pure Platelet-Rich Fibrin (P-PRF)

Breakup by Origin:

Autologous PRP
Homologous PRP
Allogeneic PRP

Breakup by Application:

Orthopedics
Cosmetic Surgery and Dermatology
Neurosurgery
General Surgery
Cardiothoracic Surgery
Urology
Ophthalmology
Others

Breakup by End User:

Hospitals and Clinics
Research Institutes
Others

Breakup by Region:

Northeast
Midwest
South
West

Competitive Landscape:
The competitive landscape of the industry has also been examined with some of the key players being Arteriocyte Medical Systems Inc. (Isto Technologies II LLC), Arthrex Inc., Depuy Synthes, Inc. (Johnson & Johnson), Dr Prp USA LLC, EmCyte Corporation, Exactech Inc., Glofinn America LLC (Glofinn Co. Ltd.), Regen Lab USA LLC, Stryker Corporation, Terumo BCT Inc. (Terumo Corporation), ThermoGenesis Holdings Inc. and Zimmer Biomet Holdings Inc. Key Questions Answered in This Report:
How has the United States platelet rich plasma market performed so far and how will it perform in the coming years?
What has been the impact of COVID-19 on the United States platelet rich plasma market?
What are the key regional markets?
What is the breakup of the market based on the product type?
What is the breakup of the market based on the origin?
What is the breakup of the market based on the application?
What is the breakup of the market based on the end user?
What are the various stages in the value chain of the industry?
What are the key driving factors and challenges in the industry?
What is the structure of the United States platelet rich plasma market and who are the key players?
What is the degree of competition in the industry?

ページTOPに戻る

目次

1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
4.1 Overview
4.2 Key Industry Trends
5 United States Platelet Rich Plasma Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast
6 Market Breakup by Product Type
6.1 Pure Platelet-Rich Plasma (P-PRP)
6.1.1 Market Trends
6.1.2 Market Forecast
6.2 Leukocyte- and Platelet-Rich Plasma (LPRP)
6.2.1 Market Trends
6.2.2 Market Forecast
6.3 Leukocyte- and Platelet-Rich Fibrin (L-PRF)
6.3.1 Market Trends
6.3.2 Market Forecast
6.4 Pure Platelet-Rich Fibrin (P-PRF)
6.4.1 Market Trends
6.4.2 Market Forecast
7 Market Breakup by Origin
7.1 Autologous PRP
7.1.1 Market Trends
7.1.2 Market Forecast
7.2 Homologous PRP
7.2.1 Market Trends
7.2.2 Market Forecast
7.3 Allogeneic PRP
7.3.1 Market Trends
7.3.2 Market Forecast
8 Market Breakup by Application
8.1 Orthopedics
8.1.1 Market Trends
8.1.2 Market Forecast
8.2 Cosmetic Surgery and Dermatology
8.2.1 Market Trends
8.2.2 Market Forecast
8.3 Neurosurgery
8.3.1 Market Trends
8.3.2 Market Forecast
8.4 General Surgery
8.4.1 Market Trends
8.4.2 Market Forecast
8.5 Cardiothoracic Surgery
8.5.1 Market Trends
8.5.2 Market Forecast
8.6 Urology
8.6.1 Market Trends
8.6.2 Market Forecast
8.7 Ophthalmology
8.7.1 Market Trends
8.7.2 Market Forecast
8.8 Others
8.8.1 Market Trends
8.8.2 Market Forecast
9 Market Breakup by End User
9.1 Hospitals and Clinics
9.1.1 Market Trends
9.1.2 Market Forecast
9.2 Research Institutes
9.2.1 Market Trends
9.2.2 Market Forecast
9.3 Others
9.3.1 Market Trends
9.3.2 Market Forecast
10 Market Breakup by Region
10.1 Northeast
10.1.1 Market Trends
10.1.2 Market Forecast
10.2 Midwest
10.1.1 Market Trends
10.1.2 Market Forecast
10.3 South
10.3.1 Market Trends
10.3.2 Market Forecast
10.4 West
10.4.1 Market Trends
10.4.2 Market Forecast
11 SWOT Analysis
11.1 Overview
11.2 Strengths
11.3 Weaknesses
11.4 Opportunities
11.5 Threats
12 Value Chain Analysis
13 Porters Five Forces Analysis
13.1 Overview
13.2 Bargaining Power of Buyers
13.3 Bargaining Power of Suppliers
13.4 Degree of Competition
13.5 Threat of New Entrants
13.6 Threat of Substitutes
14 Price Analysis
15 Competitive Landscape
15.1 Market Structure
15.2 Key Players
15.3 Profiles of Key Players
15.3.1 Arteriocyte Medical Systems Inc. (Isto Technologies II LLC)
15.3.1.1 Company Overview
15.3.1.2 Product Portfolio
15.3.1.3 SWOT Analysis
15.3.2 Arthrex Inc.
15.3.2.1 Company Overview
15.3.2.2 Product Portfolio
15.3.3 Depuy Synthes Inc. (Johnson & Johnson)
15.3.3.1 Company Overview
15.3.3.2 Product Portfolio
15.3.3.3 Financials
15.3.4 Dr Prp USA LLC
15.3.4.1 Company Overview
15.3.4.2 Product Portfolio
15.3.5 EmCyte Corporation
15.3.5.1 Company Overview
15.3.5.2 Product Portfolio
15.3.6 Exactech Inc.
15.3.6.1 Company Overview
15.3.6.2 Product Portfolio
15.3.7 Glofinn America LLC (Glofinn Co. Ltd.)
15.3.7.1 Company Overview
15.3.7.2 Product Portfolio
15.3.8 Regen Lab USA LLC
15.3.8.1 Company Overview
15.3.8.2 Product Portfolio
15.3.9 Stryker Corporation
15.3.9.1 Company Overview
15.3.9.2 Product Portfolio
15.3.9.3 Financials
15.3.9.4 SWOT Analysis
15.3.10 Terumo BCT Inc. (Terumo Corporation)
15.3.10.1 Company Overview
15.3.10.2 Product Portfolio
15.3.10.3 Financials
15.3.10.4 SWOT Analysis
15.3.11 ThermoGenesis Holdings Inc.
15.3.11.1 Company Overview
15.3.11.2 Product Portfolio
15.3.11.3 Financials
15.3.11.4 SWOT Analysis
15.3.12 Zimmer Biomet Holdings Inc.
15.3.12.1 Company Overview
15.3.12.2 Product Portfolio
15.3.12.3 Financials
15.3.12.4 SWOT Analysis